New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease

Rhea-AI Summary

Veracyte announces the presentation of four abstracts at the CHEST 2021 Annual Meeting, highlighting the clinical impact of its genomic diagnostic tests for lung cancer. The studies show that the Percepta Nasal Swab test can effectively assess cancer risk in patients with lung nodules, enhancing decision-making for treatment options. Additional findings reinforce the value of the Percepta GSC and Envisia GC in managing lung cancer and interstitial lung disease.

Positive

• Clinical validation data show Percepta Nasal Swab's effectiveness across nodule sizes and cancer stages.
• New data presented reinforce the role of genomic classifiers in improving patient care decisions.

Negative

• None.

- Expanded clinical validation data demonstrate Percepta Nasal Swab test performance across nodule sizes and cancer stages in early lung cancer assessment -

- Findings reinforce value of Percepta GSC and Envisia GC in clinical decision-making and patient care -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced that four abstracts highlighting the clinical impact of the company’s genomic diagnostic tests for lung cancer and interstitial lung disease (ILD) will be presented at the American College of Chest Physicians (CHEST) Annual Meeting 2021, being held virtually October 17-20, 2021.

The abstracts include new data from an expanded clinical validation study which demonstrate the ability of Veracyte’s Percepta Nasal Swab test to determine cancer risk in patients with lung nodules found on CT scans – across lung nodule sizes, lung cancer stages and patients’ prior-cancer status. Veracyte developed the novel noninvasive test to help physicians more accurately, quickly and confidently determine which patients can be safely directed to routine monitoring and which should proceed to further diagnostic work-up and treatment as needed.

“The Percepta Nasal Swab is a key component of Veracyte’s lung cancer portfolio and expands our ability to answer clinical questions across the patient journey in lung cancer,” said Marc Stapley, Veracyte’s chief executive officer. “Collectively, the new data that will be presented at this year’s CHEST meeting demonstrate the power of our cutting-edge genomic science and technology to help physicians and patients make better, faster and more confident care decisions in serious lung diseases.”

Additional abstracts to be presented at the CHEST meeting provide further evidence that Veracyte’s Percepta and Envisia classifiers deliver valuable genomic information that helps guide patient care in lung cancer and ILDs (including idiopathic pulmonary fibrosis), respectively.

Following are details of the four abstracts:

Date/Time:		Sunday, October 17, 9:15 a.m.-10:20 a.m. CT
Title:		A Nasal Clinical-Genomic Classifier for Assessing Risk of Malignancy in Lung Nodules Demonstrates Accurate Performance Independent of Nodule Size or Cancer Stage
Abstract #:		39959 (oral presentation)
Presenter:		Carla R. Lamb, M.D., Lahey Hospital & Medical Center
Date/Time:		Sunday, October 17, 9:15 a.m.-10:20 a.m. CT
Title:		Impact of Percepta Bronchial Genomic Classifier on Lung Nodule Management at an Academic Medical Center
Abstract #:		39994 (oral presentation)
Presenter:		Harpreet Singh, M.D., Medical College of Wisconsin
Date/Time:		Monday, October 18, 12:15 p.m.-1:20 p.m. CT
Title:		The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Interstitial Lung Disease
Abstract #:		40063 (oral presentation)
Presenter:		Joseph Lasky, M.D., Tulane University Medical School
Date/Time:		On-Demand October 17-21
Title:		Role of Next Generation Sequencing with Percepta Brushing in Reclassifying Lung Nodule Risk After Non-Diagnostic Bronchoscopy
Abstract #:		36774 (poster)
Presenter:		Abhijit Raval, M.D., AnMed Health Medical Center

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the Percepta Nasal Swab, Percepta Genomic Sequencing Classifier and Envisia Genomic Classifier. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," “suggest,” "may," "will" “prospective” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracyte’s belief that its Percepta Nasal Swab Test can significantly improve the early assessment of lung cancer and assist healthcare providers in guiding patients regarding treatment options. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 22, 2021 and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, “Know by Design” and “More about You” are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005393/en/

Investor and Media Contact:

Tracy Morris

Vice President of Corporate Communications

& Investor Relations

tracy.morris@veracyte.com

650-380-4413

Source: Veracyte, Inc.

FAQ

What are the new findings about Veracyte's Percepta Nasal Swab test presented at the CHEST 2021 Annual Meeting?

New findings show the Percepta Nasal Swab test effectively assesses cancer risk in patients with lung nodules, regardless of their size or stage.

When are Veracyte's abstracts being presented at the CHEST 2021 Annual Meeting?

The abstracts will be presented from October 17-20, 2021.

How do Veracyte's genomic classifiers impact lung cancer management?

Veracyte's genomic classifiers, including Percepta and Envisia, provide valuable information that aids in making informed treatment decisions for lung cancer and interstitial lung disease patients.

What is the significance of the data presented on the Percepta Nasal Swab test?

The data supports the Percepta Nasal Swab test's ability to guide healthcare providers in determining whether patients should undergo further diagnostic work-up or monitoring.